Abstracts tagged "remission and rheumatoid arthritis (RA)"

Abstract Number: 392 • 2012 ACR/ARHP Annual Meeting
Analysis of Factors Impact On Patient Global Assessment in Daily Practice Based On Observational Cohort IORRA (Institute of Rheumatology, Rheumatoid Arthritis)
Yasushi Inoue¹, Eiichi Tanaka², Ayako Nakajima³, Eisuke Inoue⁴, Akiko Kobayashi⁴, Daisuke Hoshi¹, Naoki Sugimoto⁴, Kumi Shidara⁴, Yohei Seto⁴, Atsuo Taniguchi⁴, Shigeki Momohara¹ and Hisashi Yamanaka¹, ¹Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ²Tokyo Women's Medical University, Tokyo, Japan, ³Rheumatology, Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan, ⁴Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan
Background/Purpose: Patient global assessment (PtGA) is an element of the new ACR/EULAR remission criteria for rheumatoid arthritis (RA). This definition has been reported to better…
Abstract Number: 2639 • 2012 ACR/ARHP Annual Meeting
Residual Disease Activity in Patients with Early Rheumatoid Arthritis Who Were Classified As Being in Remission According to 8 Different Descriptions: Post Hoc Analysis of the Etude Et Suivi Des Polyarthrites Indifférenciées Récentes (ESPOIR) Cohort
Isabel Castrejón¹, Maxime Dougados², Bernard Combe³, Francis Guillemin⁴, Bruno Fautrel⁵ and Theodore Pincus¹, ¹Rheumatology, Rush University Medical Center, Chicago, IL, ²Rheumatology B Department, Paris-Descartes University, APHP, Cochin Hospital, Paris, France, ³Rheumatology, Hopital Lapeyronie, Montpellier, France, ⁴Hopitaux de Brabois, Nancy, France, ⁵Rheumatology / GRC08-EEMOIS, APHP-Pitie Salpetriere Hospital / UPMC, Paris, France
Background/Purpose: No single gold standard for remission is available for rheumatoid arthritis (RA). All available descriptions, including 2 proposed by an ACR/EULAR committee, allow residual…
Abstract Number: 394 • 2012 ACR/ARHP Annual Meeting
Remission After One Year in ACPA Positive and ACPA Negative Patients with Early Arthritis
K.V.C. Wevers-de Boer¹, L. Heimans¹, K. Visser¹, A.A. Schouffoer², T.H.E. Molenaar³, J.B. Harbers⁴, C. Bijkerk⁵, I. Speyer⁶, M. de Buck⁷, P.B. de Sonnaville⁸, B.A. Grillet⁹, Tom Huizinga¹ and C.F. Allaart¹, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Rheumatology, Haga Hospital, The Hague, Netherlands, ³Dept of Rheumatology, Groene Hart Hospital, Gouda, Netherlands, ⁴Franciscus Hospital, Roosendaal, ⁵Rheumatology, Reinier de Graaf Gasthuis, Delft, Netherlands, ⁶Rheumatology, Bronovo Hospital, Den Haag, Netherlands, ⁷MCH, The Hague, ⁸Department of Rheumatology, Admiraal de Ruyter hospital, Goes, Netherlands, ⁹Department of Rheumatology, Zorgsaam Hospital, Terneuzen, Netherlands
Background/Purpose: To evaluate possible differences in clinical response after one year of remission steered treatment in Anti Citrullinated Protein Antibody (ACPA) positive and negative RA…
Abstract Number: 2606 • 2012 ACR/ARHP Annual Meeting
Patient Reported Outcomes in Early Arthritis Patients
L. Heimans¹, K.V.C. Wevers-de Boer¹, K. Visser¹, R. Goekoop², T.H.E. Molenaar³, B.A. Grillet⁴, Tom Huizinga¹ and C.F. Allaart¹, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Haga Hospital, The Hague, Netherlands, ³Dept of Rheumatology, Groene Hart Hospital, Gouda, Netherlands, ⁴Department of Rheumatology, Zorgsaam Hospital, Terneuzen, Netherlands
Background/Purpose: To investigate patient reported outcomes (PROs) of functioning and health related quality of life (HRQOL) after 1 year remission (DAS
Abstract Number: 396 • 2012 ACR/ARHP Annual Meeting
Prevalence, Concordance and Predictors of Early and Sustained Remission Assessed by Various Indices in the French Early Arthritis Espoir Cohort
Cédric Lukas¹, Ihsane Hmamouchi², Xavier Le Loet³, Bruno Fautrel⁴ and Bernard Combe⁵, ¹Immuno-Rhumatologie, Hopital Lapeyronie, Montpellier, France, ²El Ayachi Hospital, Rabat, Morocco, ³Rheumatology Department, CHU de ROUEN, Rouen, France, ⁴Rheumatology / GRC08-EEMOIS, APHP-Pitie Salpetriere Hospital / UPMC, Paris, France, ⁵Rheumatology, Hopital Lapeyronie, Montpellier, France
Background/Purpose: Clinical remission is the best achievable state in patients with rheumatoid arthritis (RA). The definition of remission, however, is still under debate. The aim…
Abstract Number: 2608 • 2012 ACR/ARHP Annual Meeting
Time in Remission Is Important for Improvement of Physical Function in Patients with Rheumatoid Arthritis (RA)
Helga Radner¹, Farideh Alasti², Josef S. Smolen³ and Daniel Aletaha⁴, ¹Department of Internal Medicine III; Division of Rheumatology, Medical University Vienna, Vienna, Austria, ²Department of Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ³Division of Rheumatology, Department of Internal Medicine III,, Medical University of Vienna and Hietzing Hospital, Vienna, Austria, ⁴Department of Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria
Background/Purpose: Physical function is one of the major outcomes in RA as it predicts work disability, quality of life, health care resource utilisation and mortality.…
Abstract Number: 399 • 2012 ACR/ARHP Annual Meeting
Can Sustained Remission of Rheumatoid Arthritis Be Predicted? an Analysis From the Japanese National Database of Rheumatic Disease (NinJa)
Yoichiro Haji¹, Mitsumasa Kishimoto¹, Ryo Rokutanda¹, Sachiko Ohde², Gautam A. Deshpande³, Yuri Ohara¹, Chisun Min¹, Yasuhiro Suyama¹, Hisanori Shimizu¹, Ken-ichi Yamaguchi¹, Akira Takeda⁴, Yukio Matsui¹, Masato Okada¹ and Shigeto Tohma⁵, ¹Division of Allergy & Rheumatology, St. Luke's International Hospital, Tokyo, Japan, ²Center for Clinical Epidemiology, St.Luke's Life of Science Institute, Tokyo, Japan, ³Center for Clinical Epidemiology, St. Luke's Life Science Instutute, Tokyo, Japan, ⁴Division of Clinical Immunology & Rheumatology, International University of Health and Welfare Hospital, Nasu-shiobara, Japan, ⁵Clinical Research Center for Allergy and Rheumatology, Sagamihara Hospital, National Hospital Organization, Sagamihara, Japan
Background/Purpose: Achievement of clinical remission in rheumatoid arthritis (RA) is now the goal of therapy to reduce joint damage and disability, and maintain or improve…
Abstract Number: 2610 • 2012 ACR/ARHP Annual Meeting
Predictors of Sustained Clinical Remissionin Early Rheumatoid Arthritis – Results From the Canadian Early Arthritis Cohort
Bindee Kuriya¹, Juan Xiong², Gilles Boire³, Boulos Haraoui⁴, Carol A. Hitchon⁵, Janet E. Pope⁶, J. Carter Thorne⁷, Diane Tin⁸, Edward Keystone⁹, Vivian P. Bykerk¹⁰ and CATCH¹¹, ¹Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ²Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ³Rheumatology Division, Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, QC, Canada, ⁴Osteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM), Montreal, QC, Canada, ⁵University of Manitoba, Winnipeg, MB, Canada, ⁶Medicine/Rheumatology, St. Joseph Health Care London, University of Western Ontario, London, ON, Canada, ⁷Southlake Regional Health Centre, Newmarket, ON, Canada, ⁸The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada, ⁹University of Toronto, Toronto, ON, Canada, ¹⁰Rheumatology, Hospital for Special Surgery, New York, NY, ¹¹Dr. Vivian P. Bykerk, Toronto, ON, Canada
Background/Purpose: Rapid time-to-remission has been associated with sustained remission in established rheumatoid arthritis (RA)1. However, the prevalence and predictive factors of sustained remission in early…
Abstract Number: 400 • 2012 ACR/ARHP Annual Meeting
High Patient Global Assessment Scores Associate with the Residual Disease Activity Unidentified by a 28-Joint Examination in Rheumatoid Arthritis Patients Approaching Clinical Remission
Yasushi Inoue¹, Eiichi Tanaka², Ayako Nakajima³, Eisuke Inoue⁴, Akiko Kobayashi⁴, Daisuke Hoshi¹, Naoki Sugimoto⁴, Kumi Shidara⁴, Yohei Seto⁴, Atsuo Taniguchi⁴, Shigeki Momohara¹ and Hisashi Yamanaka¹, ¹Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ²Tokyo Women's Medical University, Tokyo, Japan, ³Rheumatology, Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan, ⁴Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan
Background/Purpose: Patient global assessment (PtGA) is a component of the new ACR/EULAR remission criteria for rheumatoid arthritis (RA). It has been reported that >50% of…
Abstract Number: 2605 • 2012 ACR/ARHP Annual Meeting
Exploration of Possible Preliminary Descriptions of Remission Based On RAPID3, without Laboratory Tests or Formal Joints Counts but with Careful Joint Examinations, in the Etude Et Suivi Des Polyarthrites Indifférenciées Récentes (ESPOIR) Cohort of Early Rheumatoid Arthritis Patients
Isabel Castrejón¹, Maxime Dougados², Bernard Combe³, Bruno Fautrel⁴ and Theodore Pincus¹, ¹Rheumatology, Rush University Medical Center, Chicago, IL, ²Rheumatology B Department, Paris-Descartes University, APHP, Cochin Hospital, Paris, France, ³Rheumatology, Hopital Lapeyronie, Montpellier, France, ⁴Rheumatology / GRC08-EEMOIS, APHP-Pitie Salpetriere Hospital / UPMC, Paris, France
Background/Purpose: Criteria for remission in rheumatoid arthritis (RA) have been developed according to DAS28 (disease activity score), CDAI (clinical disease activity index), and two recent…
Abstract Number: 404 • 2012 ACR/ARHP Annual Meeting
Remission is a Difficult Target in Clinical Practice When RA Disease Is Established
Till Uhlig¹, Elisabeth Lie², Cecillie Kaufmann³, Erik Rødevand⁴, Knut Mikkelsen⁵, Synnøve Kalstad⁶ and Tore K. Kvien¹, ¹Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ³Rheumatology department, Vestre Viken, Drammen, Norway, ⁴Dept. of Rheumatology, St. Olavs Hospital, Trondheim, Norway, ⁵Lillehammer Hospital for Rheumatic Diseases, Lillehammer, Norway, ⁶Dept. of Rheumatology, University Hospital of Northern Norway, Tromsø, Norway
Background/Purpose: Clinical remission is the treatment target in rheumatoid arthritis (RA) and several composite indices are available for evaluation of remission and low disease activity…
Abstract Number: 2140 • 2012 ACR/ARHP Annual Meeting
A Longitudinal Study of Prognostic Factors in Patients with Early RA Providing Direction for Future Clinical Treatment- Predict Study
Paul Bird¹, David Nicholls², Julien P. de Jager³, Hedley Griffiths⁴, Lynden Roberts⁵, Kathleen Tymms⁶, Jane Zochling⁷, Mark H. Arnold⁸, Geoffrey O. Littlejohn⁹ and OPAL Consortium¹⁰, ¹Combined Rheumatology Practice, Sydney, Australia, ²Coast Joint Care, Maroochydore, Australia, ³Suite 2, Osler House, Southport, Australia, ⁴Barwon Rheumatology Service, Geelong, Australia, ⁵School of Medicine, James Cook University, Townsville, Australia, ⁶Canberra Rheumatology, Canberra, ACT, Australia, ⁷Menzies Research Institute Tasmania, Hobart, Australia, ⁸Orthopaedic Arthritis Spec Ctr, Level 2 The Gallery, Chatswood, Australia, ⁹Rheumatology, Monash Medical Center, Melbourne, Australia, ¹⁰Melbourne, Australia
Background/Purpose: Despite the conspicuous increase in available treatment for rheumatoid arthritis [RA], and the shift to early, more aggressive management, there is a paucity of…
Abstract Number: 405 • 2012 ACR/ARHP Annual Meeting
Frequencies of Boolean and Index Based ACR-EULAR Remissions Differ Slightly Depending On the Method of Patient Global Assessment
Paul Studenic¹, Josef S. Smolen¹ and Daniel Aletaha², ¹Department of Internal Medicine 3, Division of Rheumatology, Medical University Vienna, Vienna, Austria, ²Department of Internal Medicine 3, Division of Rheumatology, Medical University of Vienna, Vienna, Austria
Background/Purpose: Two definitions of remission have been put forward by the ACR and EULAR: a Boolean based, requiring swollen and tender joint counts (SJC, TJC),…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].